Darrin Despain

4.5k total citations · 1 hit paper
28 papers, 1.5k citations indexed

About

Darrin Despain is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Darrin Despain has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Darrin Despain's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and PARP inhibition in cancer therapy (10 papers). Darrin Despain is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and PARP inhibition in cancer therapy (10 papers). Darrin Despain collaborates with scholars based in United States, France and Australia. Darrin Despain's co-authors include Ronald Goldblum, Paul Rutgeerts, Brian G. Feagan, Remo Panaccione, Gary S. Hogge, Stephen B. Hanauer, William J. Sandborn, Stephan R. Targan, Stefan Schreiber and Jean‐Frédéric Colombel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Darrin Despain

28 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

2005 688 citations William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darrin Despain United States	14	704	550	412	322	322	28	1.5k
Tomomichi Kiyomatsu Japan	25	507 0.7×	175 0.3×	240 0.6×	79 0.2×	1.3k 4.0×	135	2.0k
Shinichiro Horiguchi Japan	21	253 0.4×	117 0.2×	224 0.5×	99 0.3×	587 1.8×	106	1.5k
Ming‐Chu Chang Taiwan	26	284 0.4×	143 0.3×	367 0.9×	60 0.2×	847 2.6×	69	1.9k
Sameh Mikhail United States	22	415 0.6×	103 0.2×	233 0.6×	50 0.2×	747 2.3×	70	1.5k
Jeffrey S. Wasser United States	20	327 0.5×	79 0.1×	231 0.6×	39 0.1×	587 1.8×	48	2.0k
Delia D’Avola Spain	25	326 0.5×	211 0.4×	726 1.8×	52 0.2×	407 1.3×	60	2.1k
Tamito Sasaki Japan	19	447 0.6×	64 0.1×	317 0.8×	85 0.3×	919 2.9×	66	1.6k
H. D. Saeger Germany	22	341 0.5×	146 0.3×	325 0.8×	60 0.2×	1.1k 3.3×	63	2.2k
Süleyman Buyukberber Türkiye	21	473 0.7×	40 0.1×	171 0.4×	102 0.3×	653 2.0×	136	1.5k
Andrew Dean Australia	17	694 1.0×	49 0.1×	131 0.3×	192 0.6×	1.1k 3.4×	104	1.6k

Countries citing papers authored by Darrin Despain

Since Specialization

Citations

This map shows the geographic impact of Darrin Despain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrin Despain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrin Despain more than expected).

Fields of papers citing papers by Darrin Despain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrin Despain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrin Despain. The network helps show where Darrin Despain may publish in the future.

Co-authorship network of co-authors of Darrin Despain

This figure shows the co-authorship network connecting the top 25 collaborators of Darrin Despain. A scholar is included among the top collaborators of Darrin Despain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darrin Despain. Darrin Despain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bryce, Alan H., Ray McDermott, Josep M. Piulats, et al.. (2025). Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.. Journal of Clinical Oncology. 43(5_suppl). 155–155. 3 indexed citations

O’Malley, David M., Domenica Lorusso, Shannon N. Westin, et al.. (2024). LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Annals of Oncology. 35. S1223–S1224. 13 indexed citations

Bryce, Alan H., Josep M. Piulats, M. Neil Reaume, et al.. (2023). Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.. Journal of Clinical Oncology. 41(6_suppl). 18–18. 10 indexed citations

Chowdhury, S., Akash Patnaik, David Campbell, et al.. (2020). 659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2. Annals of Oncology. 31. S533–S534. 2 indexed citations

Yang, James Chih‐Hsin, Karen L. Reckamp, Young‐Chul Kim, et al.. (2020). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports. 2(2). 100114–100114. 19 indexed citations

Abida, Wassim, David Campbell, Akash Patnaik, et al.. (2020). Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 178–178. 5 indexed citations

Abida, Wassim, Alan H. Bryce, Nicholas J. Vogelzang, et al.. (2019). Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.. Journal of Clinical Oncology. 37(15_suppl). 5031–5031. 4 indexed citations

Abida, Wassim, David Campbell, Akash Patnaik, et al.. (2019). Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses. Annals of Oncology. 30. v327–v328. 69 indexed citations

Abida, Wassim, Alan H. Bryce, Nicholas J. Vogelzang, et al.. (2018). Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Annals of Oncology. 29. viii272–viii272. 40 indexed citations

10.

Helman, Elena, Minh Nguyen, Chris Karlovich, et al.. (2018). Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clinical Lung Cancer. 19(6). 518–530.e7. 52 indexed citations

11.

Ryan, Charles J., Simon P. Watkins, Darrin Despain, et al.. (2017). Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. Journal of Clinical Oncology. 35(15_suppl). TPS5087–TPS5087. 3 indexed citations

12.

Wakelee, Heather A., Jonathan W. Goldman, Shirish M. Gadgeel, et al.. (2016). PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S311–S312. 1 indexed citations

13.

Gadgeel, S., J.C. Soria, Heather A. Wakelee, et al.. (2015). 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. European Journal of Cancer. 51. S628–S628. 1 indexed citations

14.

Fritz, Jason S., Christiana Blair, Ronald J. Oudiz, et al.. (2013). Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. CHEST Journal. 143(2). 315–323. 73 indexed citations

15.

Badesch, David B., Jeremy Feldman, Anne Keogh, et al.. (2011). ARIES‐3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovascular Therapeutics. 30(2). 93–99. 64 indexed citations

16.

Klinger, James R., Ronald J. Oudiz, Rebecca Spence, Darrin Despain, & Christopher Dufton. (2011). Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension. The American Journal of Cardiology. 108(2). 302–307. 28 indexed citations

17.

Kawut, Steven M., et al.. (2009). SIX-MINUTE WALK DISTANCE AND B-TYPE NATRIURETIC PEPTIDE AS DISCRIMINATORS OF SURVIVAL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. CHEST Journal. 136(4). 22S–22S. 1 indexed citations

18.

Oudiz, Ronald J., Nazzareno Galiè, Horst Olschewski, et al.. (2009). Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 54(21). 1971–1981. 176 indexed citations

19.

McGoon, Michael D., Adaani Frost, Ronald J. Oudiz, et al.. (2008). Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. CHEST Journal. 135(1). 122–129. 132 indexed citations

20.

Sandborn, William J., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2005). Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 353(18). 1912–1925. 688 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact